This notion is supported by our findings with antibodies blocking PD-L1 or PD-2 (in engineered acute leukemia cell lines expressing these ligands) as well as our findings with an activating CD28 antibody in human AML cell lines and, more importantly, several primary specimens from patients with AML. Here, CD28 is linked to acute leukemia.